thromboinflammation in therapeutic medicine - kitm.se · thromboinflammation in therapeutic...
TRANSCRIPT
Bo Nilsson, Uppsala University, Sweden
Thromboinflammation in therapeutic medicine
Höstmöte KITM 30-31th of August, 2017, Uppsala
Sowa et al, J Biomed Opt, 2017
Thromboinflammation
Clot
Inflammation
Proliferation
Remodelling
Markiewski, Trends Immunol, 2007
The cascade systems of the blood
Coagulation
Complement
C3 deficiency leads to prolonged bleeding time
Bauer et al., PlosOne, 2011
Gushiken et al., J Thromb Haemost, 2009
C3 KO mice have attenuated plateletaggregation and prolonged bleeding time
Darbousset R, Blood, 2012; 2014.
Formation of PMN (CD16+)-platelet (CD42a+) complexes in whole blood from a C3 deficient
person
Hamad, Thrombosis Haemostasis, 2015
CD16/CD42a complexesCD11b upregulation
Thrombo-inflammation
Tissue Factor
Lectin pathway
Classical pathway
Alternative pathway C3a, C5a
MBL
Ficolins
Properdin
C1q, CRP
Contact system
Tissue factor pathway
Thrombin
TF-FVII
FXII
platelets
Fibrin Fibrin
platelets
Thrombin
IschemiaCell stress
Immune complexes
Thromboinflammation triggered by
complement
Platelet
MAC
ComplementdysregulationImmune
complexes
C3aC5a
Endothelium
C3aC5aMAC
C3aC5a
1. Complement activation triggered by C1q
Hamad et al., JTH, 2009
Binding of complement components to
activated platelets
fH
Non Act. Act.0
50
100
150 **
C4BP
Non Act. Act.0
20
40
60 *
C1INH
Non Act. Act.0
25
50
75
100*
CS
Non Act. Act.0
100
200
300
400
Hamad et a., J Immunol, 2010
Blocking Complement Activation
Blocking at the C1q and C3
levels or activation in the
presence of EDTA, EGTA did
not affect the binding.
0
250
500
750
* *
**
n.s.
Hamad, J Immunol, 2010
Platelet
TRAP
PAR-1, 4C3H2O
2. C3H2O acts as a ligand for leukocyte
receptors CR1 and CR3
C3H2O acts as a ligand for:
1. CR1 (CD35)
2. CR3 (CD11b/CD18)
on PMNs and monocytes
Summary
The specificity of MASP-1 and -2
Generation of MASP-AT/C1INH Complexes by
TRAP activated platelets
MASP1/3 - AT
SERU
M
EDTA
PLA
SMA
Hiru
din P
PPPR
P 0 m
in
PRP 1
5 m
in
PRP 3
0 m
in
PRP 6
0 m
in
0
1
2
3
4
Me
an
of O
D v
alu
e
ns**
***
MASP1/3 - C1INH
Me
an
of O
D v
alu
e
SERU
M
EDTA
PLA
SMA
Hiru
din P
PPPR
P 0 m
in
PRP 1
5 m
in
PRP 3
0 m
in
PRP 6
0 m
in0
1
2
3
4ns
**
ns
MASP2 - AT
SERU
M
EDTA
PLA
SMA
Hiru
din P
PPPR
P 0 m
in
PRP 1
5 m
in
PRP 3
0 m
in
PRP 6
0 m
in
0
1
2
3
4
Me
an
of O
D v
alu
e
*
**
**
MASP2 - C1INH
Me
an o
f OD
va
lue
SERU
M
EDTA
PLA
SMA
Hiru
din P
PPPR
P 0 m
in
PRP 1
5 m
in
PRP 3
0 m
in
PRP 6
0 m
in
0
1
2
3
ns
**
Kozarcanin et al., JTH, 2016
MASP-1,-2/serpin complexes
Koz
Activation of PPP by glas
Kozarcanin et al., JTH, 2016
3. Platelet- and fibrin-mediated lectin
pathway activation
Platelet
TRAP, thrombin
PAR-1, 4
LP activation
Kozarcanin et al., JTH, 2016
1. DIC
2. Thrombotic events such as cardiac infarction, stroke and other
cardiovascular conditions
3. Biomaterials implants (joint replacements, scaffolds for tissue
engineering etc), extracorporeal treatments (hemodialysis,
cardiopulmonary bypass)
4. Pharmacological delivery systems e.g. lipid micelles, polymers, virus
vectors etc.
5. Microangiopathies- dysregulation (aHUS)
6. Cell and cell cluster transplantation and therapies.
7. Whole organ transplantation
1. Rheumatic disease (scleroderma, SLE, antiphospholipid syndrome).
Thromboinflammation is an important
pathophysiological mechanism in several clinical
conditions and treatments
1. Thromboinflammation in
hemodialysis
Ekdahl et al., Nature Rev Neph, 2017
2. Thromboinflammation in transplantation
Characterized by:
• Coagulation and complement
activation
• Platelet consumption
• Leukocyte activation and infiltration
• Cytokine generation
• Cell death
• Graft loss / delayed graft function
Mechanism:
• Antibodies and lectins• Lack of cell associated regulators
e.g. DAF, MCP, AT, C1-INH• Cell stress- cyto/chemokines, TF
expression
I/R injury
IBMIR
Ischemia/reperfusion injury
Conjugation of peptides or macromolecules phospholipid
PEG-phospholipid linker
-Cys-
PEG
Engberg, Biomaterials, 2009, Nilsson Biomaterials, 2012; Asif, Acta Biomaterialia, 2015
Hydrophobic
interaction
Short peptide-
PEG-lipid
Heparin conjugates
Cell membrane
0
200
400
600
800
1000
1200
0 20 40 60
An
gle
sh
ift
(mD
A)
Time (min)
control peptide
HBPIII
CHC AT
Asif, Acta Biomaterialia, 2015
Heparin-coating
Inflammation, cytolysis (C5a, C3a)
Recruited factor H
Immobilized apyrase(CD39)
A. Regulation of the complement system
Platelet aggregation
B. Regulation of platelet activation (and coagulation system)
Regulation of the complement and coagulation
system by autoregulation
Teramura, Biomaterials, 2013
Slide chamber model experiment
Microscope slide glass
Porcine aortic endothelial cells
Factor H on PAEC after exposure with whole blood
5% fH-bp-PEG-
lipid/PAEC Control PAEC
Nilsson, Biomaterials, 2013
Whole blood experiment on
Apyrase/5C6-immobilized surface
(a) (b)
(c) (d)
Protection of transplanted kidneys against I/R in two models
Donors
n=6
Recipient A, not
related to donor
(n=6)
Recipient B, not
related to donor
(n=6)
Long-term, allogeneic
Donors
N=7
Recipient, not
related to donor
(n=7)
En bloc, short-term
Binding of PEG-phospholipid
*
50 100 150 200 250 300 350 400 450 500 550 600 650 7000
2×107
4×107
6×107
8×107
1×108
Time (min) post reperfusion
C3b
dep
osit
ion
in
kid
ney
Den
isto
metr
ic s
um
ControlTreated
50 100 150 200 250 300 350 400 450 500 550 600 650 7000
2×107
4×107
6×107
8×107
Time (min) post reperfusion
C4d
dep
osit
ion
in
kid
ney
De
nis
tom
etr
ic s
um
Control
Treated
50 1001502002503003504004505005506006507000
1×108
2×108
3×108
4×108
Time (min) post reperfusion
C5aR
dep
osit
ion
in
kid
ney
Den
isto
metr
ic s
um Control
Treated
50 100 150 200 250 300 350 400 450 500 550 600 650 7000
1×108
2×108
3×108
Time (min) post reperfusionM
AC
dep
osit
ion
in
kid
ney
Den
isto
metr
ic s
um
Control
Treated
*
Complement deposition
** ** **** *** *** *** *** ***
**
*
Coagulation and Complement activation
*** **
*
*
Diuresis
To
tal d
iure
sis
(m
l) d
uri
ng
360 m
in p
ost
tx
Control PEG-phospholipid0
20
40
60
80
Control
PEG-phospholipid
n=6
*
3A
Control PEG-phospholipid
construct
Cytokines
Inflammatory markers
0.1
0.25
0.50 1 24 48 72 96 12
0
0
100
200
300
400
500
Time (hour) post reperfusion
MC
P-1
(p
g/m
l)
Control (n=3)
PEG-lipid (n=7)
0.1
0.25
0.50 1 24 48 72 96 12
0
0
200
400
600
800
Time (hour) post reperfusion
Control (n=3)PEG-lipid (n=7)
TN
F@
(p
g/m
l)
Plasma Creatinine
Kidney function marker
Time (hour) post reperfusion
Pla
sm
a C
reati
nin
e u
mo
l/L
24 48 72 96 120
0
500
1000
1500Control (n=4)PEG lipid (n=7)
*
**
*
Summary
1. PEG/phospholipid-linked regulators are efficientregulators of these reactions in vitro
2. Also the PEG/phospholipid linker alone has a significant effect on I/R injury in vivo
Sana Asif
Karin Fromell
Jaan Hong
Rolf Larsson
Peetra Magnusson
Kristina Nilsson Ekdahl
Uppsala Universitet
Yuji Teramura
Tokyo University/Uppsala University
Marianne Waern Jensen
Swedish Agricultural University, Uppsala
Alireza Bigliarnia
Lund University
Peter GarredCopenhagen University
John LambrisDaniel RicklinPennsylvania University
Markus Huber-LangUlm University, Ulm
Per NilssonOslo UniversityLinneus University
John LambrisDaniel RicklinPennsylvania University
Trian ChavakisIannis KourtzelisDresden TechnicalUniversity
Tack!